Suresh Singh Yadav1, Chandra Bhushan Prasad1, Shyam Babu Prasad1, Lakshmi Kant Pandey2, Sunita Singh3, Satyajit Pradhan4, Gopeshwar Narayan5. 1. Department of Molecular and Human Genetics, Banaras Hindu University, Varanasi 221005, India. 2. Department of Obstetrics and Gynaecology, Banaras Hindu University, Varanasi 221005, India. 3. Department of Zoology, Mahila Mahavidyalaya, Banaras Hindu University, Varanasi 221005, India. 4. Department of Radiotherapy & Radiation Medicine, Banaras Hindu University, Varanasi 221005, India. 5. Department of Molecular and Human Genetics, Banaras Hindu University, Varanasi 221005, India. Electronic address: gnarayan@bhu.ac.in.
Abstract
AIM: The fundamental events for cancer progression and metastases include loss of cell adhesion, cell proliferation, anchorage-independent cell growth (evading anoikis), cell migration and cell invasion. All these events leading to cancer progression happen in a favorable nurturing tumor microenvironment. This study was designed to explore the anti-tumor activity of staurosporine (a nonspecific protein kinase inhibitor) in the tumor microenvironment of cervical cancer. MAIN METHODS: The anti-tumor activity of staurosporine was investigated by cell adhesion assay, colony formation assay, apoptosis assay and quantitative real-time polymerase chain reaction (PCR) in cervical cancer cell lines. KEY FINDINGS: The cell adhesion assay showed that staurosporine induces adhesion of cervical cancer cells to the extracellular matrix (ECM) protein fibronectin. The soft agar colony formation assay showed that staurosporine inhibits both the number and size of colony formation in a dose dependent manner and also induces adherent tendency in the cancer cells. Staurosporine also induces prominent apoptosis in single cell suspensions compared to adherent cells. Stroma cell induced transcription of matrix metalloprotease 1 (MMP1) and matrix metalloprotease 2 (MMP2) in cervical cancer cells was inhibited by staurosporine. SIGNIFICANCE: Our results indicate that staurosporine induces anti-tumor response in the cervical tumor microenvironment by inhibiting the fundamental events for cancer progression and metastases. The present study represents an attractive area for further research and opens up new avenues towards the understanding of cervical cancer therapeutics.
AIM: The fundamental events for cancer progression and metastases include loss of cell adhesion, cell proliferation, anchorage-independent cell growth (evading anoikis), cell migration and cell invasion. All these events leading to cancer progression happen in a favorable nurturing tumor microenvironment. This study was designed to explore the anti-tumor activity of staurosporine (a nonspecific protein kinase inhibitor) in the tumor microenvironment of cervical cancer. MAIN METHODS: The anti-tumor activity of staurosporine was investigated by cell adhesion assay, colony formation assay, apoptosis assay and quantitative real-time polymerase chain reaction (PCR) in cervical cancer cell lines. KEY FINDINGS: The cell adhesion assay showed that staurosporine induces adhesion of cervical cancer cells to the extracellular matrix (ECM) protein fibronectin. The soft agar colony formation assay showed that staurosporine inhibits both the number and size of colony formation in a dose dependent manner and also induces adherent tendency in the cancer cells. Staurosporine also induces prominent apoptosis in single cell suspensions compared to adherent cells. Stroma cell induced transcription of matrix metalloprotease 1 (MMP1) and matrix metalloprotease 2 (MMP2) in cervical cancer cells was inhibited by staurosporine. SIGNIFICANCE: Our results indicate that staurosporine induces anti-tumor response in the cervical tumor microenvironment by inhibiting the fundamental events for cancer progression and metastases. The present study represents an attractive area for further research and opens up new avenues towards the understanding of cervical cancer therapeutics.
Authors: Irasema Oroz-Parra; Mario Navarro; Karla E Cervantes-Luevano; Carolina Álvarez-Delgado; Guy Salvesen; Liliana N Sanchez-Campos; Alexei F Licea-Navarro Journal: Toxins (Basel) Date: 2016-02-05 Impact factor: 4.546
Authors: Joelle N Zambrano; Christina J Williams; Carly Bess Williams; Lonzie Hedgepeth; Pieter Burger; Tinslee Dilday; Scott T Eblen; Kent Armeson; Elizabeth G Hill; Elizabeth S Yeh Journal: Oncotarget Date: 2018-11-13
Authors: Karen Y Velasco-Alzate; Anelize Bauermeister; Marcelo M P Tangerina; Tito M C Lotufo; Marcelo J P Ferreira; Paula C Jimenez; Gabriel Padilla; Norberto P Lopes; Letícia V Costa-Lotufo Journal: Mar Drugs Date: 2019-11-28 Impact factor: 5.118